The number of CD163 positive macrophages is associatedwith more advanced skin melanomas, microvessels density and patient prognosis

Foks, Maciej; Wągrowska-Danilewicz, Małgorzata; Danilewicz, Marian; Bonczysta, Marta; Olborski, Bogusław; Stasikowska-Kanicka, Olga

doi:10.5114/pjp.2019.90399

Cited by 6 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, they found that M1 macrophage accumulation in the tumor stroma was correlated with the Breslow thickness and Clark level, and the abundance of M1 macrophages in malignant melanomas was associated with distant metastasis and was inversely correlated with OS, especially when located at the invasive front. 21 On the other hand, Foks et al 27 found that intratumoral M1 macrophage infiltration was not associated with the skin depth of the melanoma, and they observed significant positive correlations between the abundance of iNOS-positive cells and survival times.…”

Section: Discussionmentioning

confidence: 99%

The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanoma

Asai,

Yanagawa,

Osakabe

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

BackgroundTumor‐associated macrophages (TAMs) are an immune component of the cutaneous malignant melanoma (CMM) microenvironment and affect tumor growth. TAMs can polarize into different phenotypes, that is, proinflammatory M1 and anti‐inflammatory M2 macrophages. However, the role of the macrophage phenotype in CMM remains unclear.MethodsWe examined 88 patients with CMM. Tissue microarrays were constructed, and the density of M1 and M2 macrophages was analyzed by immunohistochemistry. Immune cells coexpressing CD68 and phosphorylated signal transducer and activator of transcription 1 (pSTAT1) were considered M1 macrophages, whereas those coexpressing CD68 and c‐macrophage activating factor (c‐Maf) were defined as M2 macrophages. These TAMs were counted, and the relationships between the density of M1 and M2 macrophages and clinicopathological factors including prognosis were investigated.ResultsThe CD68/c‐Maf score ranged from 0 to 34 (median: 5.5). The patients were divided based on the median score into the CD68/c‐Maf high (≥5.5) and low (<5.5) expression groups. Univariate and multivariate analyses revealed that CD68/c‐Maf expression was an independent predictive factor for progression‐free survival and an independent prognostic factor for overall survival. CD68/pSTAT1 expression was found in only two patients.ConclusionWe suggest that CD68/pSTAT1 coexpression is rarely observed in patients with CMM, and high CD68/c‐Maf expression is a predictor of worse prognosis in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanoma

Asai,

Yanagawa,

Osakabe

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…TAMs sense hypoxia in avascular areas of tumors and react in turn by releasing proangiogenic factors such as FGF-2, TNF-a, and VEGFs, which again promotes tumor oxygenation by the direct recruitment of endothelial cells (58,59). Given that, increased CD163+ TAMs has been shown to be correlated with increased microvessel density and angiogenesis (60)(61)(62). Herein, the decrease of these CD163+ TAMs noticed within melanomas could be involved to limit the endothelial cell recruitment through decreased growth factors excretion, and finally explain the increase in tumor necrosis as observed under Phenacetinum 4CH treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Respiration was monitored throughout the entire scan. For Matrigel ® plug assay, images were acquired using a threedimensional (3D) T2-weighted fast spin echo sequence (FSE) coronal T2-weighted fast spin echo sequence (FSE) with echo time (TE)/repetition time (TR) = 68/5000 ms, 60…”

Section: Mri Imagingmentioning

confidence: 99%

Anti-Tumoral and Anti-Angiogenic Effects of Low-Diluted Phenacetinum on Melanoma

et al. 2021

View full text Add to dashboard Cite

Melanoma is the most aggressive form of skin cancer and the most rapidly expanding cancer in terms of worldwide incidence. If primary cutaneous melanoma is mostly treated with a curative wide local excision, malignant melanoma has a poor prognosis and needs other therapeutic approaches. Angiogenesis is a normal physiological process essential in growth and development, but it also plays a crucial role in crossing from benign to advanced state in cancer. In melanoma progression, angiogenesis is widely involved during the vertical growth phase. Currently, no anti-angiogenic agents are efficient on their own, and combination of treatments will probably be the key to success. In the past, phenacetin was used as an analgesic to relieve pain, causing side effects at large dose and tumor-inducing in humans and animals. By contrast, Phenacetinum low-dilution is often used in skin febrile exanthema, patches profusely scattered on limbs, headache, or flushed face without side effects. Herein are described the in vitro, in vivo, and ex vivo anti-angiogenic and anti-tumoral potentials of Phenacetinum low-dilution in a B16F1 tumor model and endothelial cells. We demonstrate that low-diluted Phenacetinum inhibits in vivo tumor growth and tumor vascularization and thus increases the survival time of B16F1 melanoma induced-C57BL/6 mice. Moreover, Phenacetinum modulates the lung metastasis in a B16F10 induced model. Ex vivo and in vitro, we evidence that low-diluted Phenacetinum inhibits the migration and the recruitment of endothelial cells and leads to an imbalance in the pro-tumoral macrophages and to a structural malformation of the vascular network. All together these results demonstrate highly hopeful anti-tumoral, anti-metastatic, and anti-angiogenic effects of Phenacetinum low-dilution on melanoma. Continued studies are needed to preclinically validate Phenacetinum low-dilution as a complementary or therapeutic strategy for melanoma treatment.

show abstract

“…For example, CD163 in macrophages predicts advanced cutaneous melanoma and poor prognosis. 164 CD163 can also be found on the membranes of tumor cells. A recent investigation has indicated that CD163 takes part in the tumor growth of GBM.…”

Section: Scavenger Receptor Cd163mentioning

confidence: 99%

Roles of Tumor-Associated Macrophages in Tumor Environment and Strategies for Targeting Therapy

Liu,

Zhang,

Zhu

2023

Pharmaceutical Fronts

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) constitute a significant component of the tumor microenvironment. This work reviewed the latest progress in comprehending the function of TAMs and their strategies for cancer therapy. TAMs are highly heterogeneous and plastic and exhibit different functional phenotypes in response to different signal stimuli. The emergence of single-cell technologies allows us to revisit their diversity in cancer. When their pro-inflammatory function is activated, antitumor TAMs support and activate adaptive immune cells to eliminate cancer cells through T cell-mediated killing. In the context of cancer, anti-inflammatory TAMs play a variety of pro-tumor functions, such as releasing cytokines to promote the recruitment of bone marrow cells, promoting tumor angiogenesis, and inhibiting cytotoxic T cell function. The plasticity of TAMs makes them a potential tumor therapeutic target, so finally, we updated strategies for targeting TAMs and the TAM-targeting agents currently being evaluated in clinical trials.

show abstract

The number of CD163 positive macrophages is associatedwith more advanced skin melanomas, microvessels density and patient prognosis

Cited by 6 publications

References 17 publications

The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanoma

The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanoma

Anti-Tumoral and Anti-Angiogenic Effects of Low-Diluted Phenacetinum on Melanoma

Roles of Tumor-Associated Macrophages in Tumor Environment and Strategies for Targeting Therapy

Contact Info

Product

Resources

About